Skip to main content

Table 2 Cost and effect of ACTH and TCH within five years

From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

Item Status ACTH TCH Deviation
Effect Disease Free Survival/% 38% 46% − 8
  Death/% 2.6% 1.4% 1.2
  QALY/Year 3.4 3.65 − 0.25
Intervention costsa($)   3112 1352  
Health system costs($)   56,425 45,043  
Cost($)   59,537 46,395 13,142
ICER     − 52,568
  1. aOther costs included were those of the prevention and treatment of febrile neutropenia and peripheral neuropathy
\